EUCTR2021-002252-36-DE进行中（未招募）1 期
A prospective, randomized, double-blind placebo-controlled multicentre study with 10 000 mTU/mL mannan-conjugated birch pollen allergoids administered subcutaneously to patients with birch pollen-induced allergic rhinitis or rhinoconjunctivitis.
Inmunotek S.L.0 个研究点目标入组 360 人开始时间: 2021年6月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet all of the following inclusion criteria in order to participate in this study:
- •Signed and dated Informed Consent Form by a legally competent patient,
- •Female, male or diverse patients aged 18 to 64 years,
- •Being in good physical and mental health,
- •Confirmed normal renal and liver function, including non-clinically significant deviations outside the reference ranges (< grade 2 according to the FDA Guidance for Industry for preventive Vaccine Trials (FDA 2007) at screening visit*),
- •For females: non-pregnant, non-lactating with adequate contraception as defined in chapter VI.1, or females unable to bear children (i.e., tubal ligation, hysterectomy, or post-menopausal [defined as a minimum of one year since the last menstrual period]),
- •Having the diagnosis of birch pollen allergy based on all the following criteria:
- •-A medical history of moderate to severe allergic rhinoconjunctivitis for birch pollen allergens for at least 2 previous seasons (definition of allergy severity according to ARIA),
- •-A positive skin prick test (SPT - wheal diameter =3 mm) to birch pollen allergens, positive control (histamine) wheal =3 mm, negative control (NaCl) wheal <2 mm,
- •-Specific IgE against birch pollen allergens (minimum CAP class 3 or higher, =3.5 kU/L),
- •Being treated with anti-allergic medication for at least 2 seasons prior to enrolment,
- •For asthmatic patients: confirmed diagnosis of controlled asthma during the treatment period according to Global Initiative for Asthma (GINA) guidelines (steps 1-3, GINA 2021),
- •FEV1 =80% of the patient’s reference value or Peak Expiratory Flow (PEF) =80% of the patients´ individual optimal value (for asthmatic patients only).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 360
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Simultaneous participation in other clinical trials or previous participation within 30 days before inclusion,
- •Previous immunotherapy with birch pollen allergens within the last 5 years,
- •Ongoing immunotherapy with birch pollen allergens or any other allergens,
- •Patients with acute allergic rhinoconjunctivitis due to other environmental allergens during the study period,
- •Patients with a sensitization to other environmental allergens (e.g., house dust mites, cat dander, dog dander) and whose CAP class of the respective allergen specific IgE is equal or higher than for birch pollen specific IgE,
- •Being in any relationship or dependence with the Sponsor, CRO and/or Investigator,
- •Inability to understand instructions/study documents,
- •Patients who do not have access to a smartphone/tablet (iOS or Android)#,
- •History of severe systemic reactions and/or anaphylaxis, including to food (e.g., peanut, marine animals) or to Hymenoptera venom (e.g., bee, wasp stings) or to medication (e.g., penicillin), etc.,
- •Patients who have a suspected or symptoms of a SARS-COV-2 infection, who have had contact with a confirmed case of COVID-19.
- •History of hypersensitivity to the excipients of the investigational product or placebo,
- •Mild persistent to severe persistent asthma, partly controlled or uncontrolled asthma according to GINA guidelines (GINA 2021) during the treatment period,
- •Chronic asthma or emphysema, particularly with a forced expiratory volume in 1 second (FEV1) <80% of the patient’s reference value (ECSC) or Peak Expiratory Flow (PEF) <80% of the patients’ individual optimal value,
- •History of a respiratory tract infection and/or exacerbation of asthma within 4 weeks before the screening,
- •History of significant renal disease or chronic hepatic disease,
- •Malignant active disease (ongoing or within the five past years),
- •Severe autoimmune disease,
- •Immune defects including immunosuppression, immunopathies,
- •Vaccination during the entire treatment period, except flu and SARS-CoV-2 vaccinations – see Chapter Non-allowed drugs and procedures”,
- •Use of systemic immunosuppressive medications (e.g., methotrexate or cyclosporine A) or blood transfusion one month before screening,
- •General inflammatory, severe acute or chronic inflammatory diseases,
- •Other chronic diseases such as severe congestive heart failure, cardiovascular insufficiency, active gastric ulcer, inflammatory bowel disease, uncontrolled diabetes mellitus, etc.
- •Intake of antidepressant drugs with potent antihistamine properties such as tricyclic antidepressants (e.g., doxepin, amitriptyline, desipramine, imipramine, etc.),
- •Administration or planned administration of anti-IgE antibodies, mast cell stabilizers or anti-leukotriene agents,
- •Intake of beta-blockers/ACE inhibitor medication (angiotensin-converting enzyme inhibitor),
- •Active tuberculosis,
- •Having any contraindication for the use of adrenaline (including hyperthyroidism),
- •Known positive serology to Human Immunodeficiency Virus-1/2, Hepatitis B Virus or Hepatitis C Virus,
- •Females who are pregnant, lactating, or of child-bearing potential and not using an adequate contraceptive method,
- •Administration of corticosteroids (oral, topic or nasal) or of anti-histaminic drugs within a defined time period preceding the trial (screening visit), as defined in the protocol, exception made for routine (previously prescribed) control medication for asthmatic patients,
- •Clinically relevant laborator
研究者
相似试验
进行中（未招募）
不适用
A prospective, randomized, double-blind placebo-controlled multi-centre dose-finding study of 3 different regimens of gpASIT+TM administered subcutaneously to adult patients suffering from hay feverTreatment of seasonal grass pollen rhinoconjunctivitisMedDRA version: 16.1Level: LLTClassification code 10019170Term: Hay feverSystem Organ Class: 100000004870EUCTR2013-005445-37-DEBioTech Tools s.a.
进行中（未招募）
1 期
A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered subcutaneously to adolescent and adult patients with birch pollen-induced allergic rhinitis or rhinoconjunctivitis.CTIS2023-508013-16-00CCDRD Cooperative Clinical Drug Research and Development AG600
进行中（未招募）
1 期
A prospective, randomized, double-blind placebo-controlled dose-finding study of different regimens of mannan-conjugated allergoids of birch pollen allergens administered subcutaneously to patients suffering from birch pollen-induced hay feverTreatment of birch pollen-induced allergic rhinitis or rhinoconjunctivitisMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853EUCTR2018-002522-23-DEInmunotek S.L.200
进行中（未招募）
1 期
A phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in AML patients undergoing allo-HCT (MO-TRANS Study)Adjunctive and maintenance treatment to HCTMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002864-36-DEPriothera S.A.S.249
招募中
3 期
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCTAacute myeloid leukemia (AML)JPRN-jRCT2011230008Kueenburg Elisabeth30